Azapropazone

Azapropazone
Azapropazone molecule
Clinical data
Trade namesRheumox
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Elimination half-life20 hours
Identifiers
IUPAC name
  • (RS)-5-(Dimethylamino)-9-methyl-2-propyl-1H-pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.033.543 Edit this at Wikidata
Chemical and physical data
FormulaC16H20N4O2
Molar mass300.362 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
SMILES
  • O=C3N/1N(c2c(\N=C\1N(C)C)ccc(c2)C)C(=O)C3CCC
InChI
  • InChI=1S/C16H20N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h7-9,11H,5-6H2,1-4H3 checkY
  • Key:MPHPHYZQRGLTBO-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Azapropazone is a nonsteroidal anti-inflammatory drug (NSAID). It is manufactured by Goldshield under the tradename Rheumox.[1]

It was available in the UK as a prescription-only drug, with restrictions due to certain contra-indications and side-effects.[2] Azopropazone has now been discontinued in the British National Formulary.

Azapropazone has a half-life of approximately 20 hours in humans and is not extensively metabolized.[3]

References

  1. ↑ "Rheumox Capsules". South Africa Electronic Package Inserts. Archived from the original on 2008-05-15. Retrieved 2008-08-18.
  2. ↑ "Azapropazone". Patient UK. Archived from the original on 12 April 2009.
  3. ↑ Jones CJ (1976). "The pharmacology and pharmacokinetics of azapropazone - a review". Current Medical Research and Opinion. 4 (1): 3–16. doi:10.1185/03007997609109361. PMID 770078.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.